CA-SIDE
SIDE, award-winning games industry audio provider, known for their twenty-five years of cutting-edge work within the global entertainment market, announced today that they were the exclusive English Language voice production partner to CD PROJEKT RED on the highly-anticipated open world game, Cyberpunk 2077.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005295/en/
SIDE cited some impressive stats from this project, including 2,500 hours spent recording voice performances for the game. “We knew that this would be a massive undertaking,” said Los Angeles Head of Studio Jacquie Shriver Sladeck. “Between London and LA, we delivered 117,586 total audio files to the team at CDP.”
Borys Pugacz-Muraszkiewicz, English Adaptation Director, CDPR noted, “The project was unprecedented in terms of scope and complexity. If you look at line numbers and cast size and, above all, at cast diversity - we went so far beyond the Witcher series it’s crazy. And I venture to say SIDE delivered on these aspects as few other outfits could or would even dare to try. SIDE made skilled production and engineering staff, directors and talent available to us throughout the project – a not insignificant span of time. And they did so at multiple sites, often on short notice. Quality services, world-class results, work that pushes the creative envelope - that’s what we rely on SIDE to provide.”
The connection with CD PROJEKT RED has been long-term for SIDE. “We’ve been lucky enough to work on some amazing and highly-anticipated titles in the past. It’s very exciting to get on board with projects like this – they have complex characters, big stories, lots to work with! Then you roll up your sleeves and get to work alongside the devs, figuring out what’s needed, by when, and how we’re going to do it. Our own quality threshold is high, so we knew we would be able to deliver,” says Sini Downing, Head of Production at SIDE London.
Martin Vaughan CDG, SIDE’s in-house Casting Director, says, “The great thing about working with CDPR is that the worlds they create are conceived in such a vivid and specific way. For casting, it’s fantastic because it really helps to give a clear vision of what we’re aiming for and the type of performers that will be required to bring these characters to life. They were very generous throughout all stages of casting, providing us with early character art, detailed backstories and rough cuts of cinematics to help ground who these characters were and the context they existed in.”
Jacquie Shriver Sladeck concluded, “We have been so honored to work on Cyberpunk 2077. It’s been almost three years of collaboration with CD PROJEKT RED and now we can’t wait to play the game along with the rest of the players eagerly anticipating this title.”
About SIDE
SIDE works at the cutting edge of interactive media as a provider of audio services for the global entertainment market. With over 25 years’ experience, an international network of resources and state-of-the-art studios, SIDE’s award-winning team of technical and creative experts still hold the same collective intention: To develop the truest interpretation of each client’s vision - for audiences of every genre, on any platform, in all languages.
SIDE is part of the PTW family of brands. PTW is a boutique games services company that provides custom solutions worldwide. PTW believes in accelerating innovation across the globe. They do this with their 25 years of games industry experience and 35 studios across the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005295/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
